Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401.

Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401. Clin Cancer Res. 2023 12 01; 29(23):4784-4796.

View in: PubMed

subject areas

Antineoplastic Combined Chemotherapy Protocols
Dendritic Cells
Dexamethasone
Granulocyte-Macrophage Colony-Stimulating Factor
Hematopoietic Stem Cell Transplantation
Humans
Multiple Myeloma
Transplantation, Autologous

authors with profiles

Thinle Chodon